Australia's Immutep jumps most in a year on Phase 2 trial results
17/05/2023 05:30
** Shares of Immutep IMM.AX rise as much as 11.7% to
A$0.263, highest intraday rise since Mar 21, 2022
** The biotech co says its cancer treatment drug Efti, in
combination with Merck & Co's pembrolizumab, has achieved
initial Overall Survival in the Phase-II trial for non-small
cell lung cancer
** Shares hit highest since May 5
** Stock has fallen ~14.6% this year, as of last close
(Reporting by Archishma Iyer in Bengaluru)
((Archishma.Iyer@thomsonreuters.com;))